NCX 470 has entered regulatory review in China after Ocumension Therapeutics submitted a New Drug Application for the experimental glaucoma eye drop to the Center for Drug Evaluation of China’s National Medical Products Administration. The application seeks approval to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension and uses the same core clinical package recently submitted for regulatory review in the United States.
The filing moves Nicox SA’s lead ophthalmology asset into regulatory review in two of the world’s major pharmaceutical markets within roughly six weeks. Kowa Company, Ltd. submitted the United States New Drug Application on July 1, 2026, while Phase 3 trials intended to support a Japanese filing have been underway since summer 2025. Nicox SA expects several regulatory, clinical and commercial milestones for NCX 470 during the next 12 to 18 months.
The Chinese application is supported by the Mont Blanc and Denali Phase 3 trials. Denali included clinical sites in China, allowing the same dossier used for the United States application to satisfy the clinical requirements underlying the Chinese submission. Both trials met their primary efficacy objectives, providing replicated evidence that once-daily NCX 470 can lower intraocular pressure at least as effectively as latanoprost, a widely used first-line glaucoma medicine.
Denali and Mont Blanc give the China filing a replicated Phase 3 efficacy package
The Denali Phase 3 trial enrolled 696 patients with open-angle glaucoma or ocular hypertension across 90 sites in the United States and China. Participants received either NCX 470 0.1% or latanoprost 0.005%, with efficacy assessed through time-matched intraocular pressure measurements at six points covering weeks two and six and month three.
NCX 470 achieved the trial’s primary endpoint of non-inferiority to latanoprost. Intraocular pressure reductions from baseline ranged from 7.9 to 10.0 millimeters of mercury with NCX 470 compared with 7.1 to 9.8 millimeters of mercury for latanoprost. NCX 470 produced statistically greater reductions at three of the six measured time points and numerically greater reductions at five, although the study did not satisfy its overall prespecified secondary endpoint for statistical superiority.
That distinction matters when interpreting the clinical profile. The Phase 3 program established the efficacy required to support regulatory filings, but it did not demonstrate across-the-board superiority over latanoprost. The strongest case for NCX 470 therefore rests on consistent intraocular pressure control combined with a differentiated dual mechanism rather than a claim that it universally outperforms existing prostaglandin therapy.
The earlier Mont Blanc Phase 3 trial produced broadly similar findings. NCX 470 reduced intraocular pressure by between 8.0 and 9.7 millimeters of mercury, compared with between 7.1 and 9.4 millimeters of mercury for latanoprost, and met the primary non-inferiority requirement. The consistency between two large Phase 3 trials strengthens the evidence package because the efficacy pattern was reproduced in separate patient populations.
Safety will remain part of the regulatory assessment. In Denali, conjunctival hyperemia was reported in 22% of patients receiving NCX 470 compared with 9.2% of those receiving latanoprost. No ocular serious adverse events or treatment-related non-ocular serious adverse events were reported in the NCX 470 group. Discontinuation rates through the long-term safety period were 10.1% with NCX 470 and 6.6% with latanoprost.
Nitric oxide gives NCX 470 a second pathway for lowering pressure inside the eye
NCX 470, also known as bimatoprost grenod, combines bimatoprost with Nicox SA’s nitric oxide-donating technology in a single molecule. The drug is designed to release both components after administration to the eye, allowing the two mechanisms to increase aqueous humor drainage through different pathways.
Prostaglandin analogs such as bimatoprost primarily improve uveoscleral outflow, while nitric oxide can enhance drainage through the conventional trabecular pathway through soluble guanylate cyclase signaling. The goal is to obtain additional pressure reduction without requiring patients to administer separate medications.
Lowering intraocular pressure remains the principal modifiable treatment target in glaucoma. The disease can progressively damage the optic nerve and result in irreversible vision loss, making reliable long-term pressure control central to treatment.
NCX 470 would enter a well-established market with numerous topical medicines and combination therapies. Its commercial relevance will therefore depend not only on obtaining approval but also on whether ophthalmologists consider the degree and consistency of additional pressure lowering meaningful enough to change prescribing behavior.
The once-daily dosing schedule should help avoid an obvious convenience disadvantage compared with standard prostaglandin analogs. The higher rate of ocular redness observed in Phase 3 could work in the opposite direction, particularly if the efficacy difference is modest for an individual patient.
China could follow the United States closely if the regulatory reviews proceed as expected
China does not have a fixed statutory approval period for every pharmaceutical application, but Nicox SA said approvals are frequently granted within approximately 12 to 18 months after filing. The company currently expects Chinese approval after a potential United States approval, which it projects for summer 2027 assuming a standard 12-month United States review. A United States commercial launch is expected during the second half of 2027 if the drug is approved.
These dates remain management expectations rather than regulatory commitments. Either authority could request additional information, extend its review or decline the application. An NDA submission confirms that a development package has reached formal review; it does not guarantee marketing authorization.
The China filing nevertheless materially advances the globalization of the program. Ocumension Therapeutics holds NCX 470 rights across China, South Korea and Southeast Asian markets and has already paid Nicox SA €18 million in licensing fees. The partner also funded half of the Denali trial costs. Nicox SA is entitled to tiered royalties ranging from 6% to 12% on NCX 470 sales generated by Ocumension Therapeutics.
Ocumension Therapeutics already operates an ophthalmology commercial organization in China and markets Nicox SA’s ZERVIATE allergic conjunctivitis treatment there. That existing infrastructure could reduce the time and investment required to build a separate commercial organization for NCX 470 if approval is obtained.
Kowa Company, Ltd. controls NCX 470 development and commercialization across the rest of the world, excluding the territories licensed to Ocumension Therapeutics. The United States filing triggered a €3 million payment to Nicox SA, with additional regulatory and commercial milestones and royalties available under the partnership.
This partnership structure limits Nicox SA’s direct commercialization costs while leaving the company exposed to future royalty income. It also means execution increasingly depends on its partners and regulatory authorities rather than on Nicox SA running another large global Phase 3 program itself.
Nicox shares show a measured response as NCX 470 moves closer to commercialization
Nicox SA shares were trading around €0.39 on August 10, compared with a previous close near €0.38. The stock remains listed on Euronext Growth Paris under the ALCOX ticker, with roughly 98 million shares outstanding as of July 31.
The relatively modest market response suggests investors largely expected the China application after Nicox SA received positive pre-submission feedback in June and completed the United States filing in July. The China submission still removes another execution step between NCX 470 and potential recurring royalty revenue, but the larger valuation events are likely to be regulatory decisions and subsequent commercial uptake. This interpretation is an inference from the trading pattern rather than a confirmed explanation from investors.
The next 12 to 18 months could therefore be unusually consequential for NCX 470. Regulatory review is underway in the United States and China, Phase 3 development continues in Japan, and Nicox SA has established commercial partners covering the major global markets.
Two successful Phase 3 trials have substantially reduced the clinical efficacy uncertainty surrounding the program. Regulatory approval, competitive positioning against inexpensive prostaglandin analogs and real-world prescribing will now determine whether the differentiated nitric oxide mechanism translates into a commercially meaningful glaucoma franchise.
